Table 1 Clinicopathologic characteristics of all 1396 patients with lymph node negative ER+/HER2- breast cancer and RS < 18 (all percentages within columns)
|  | RS 0–10 (n = 505) | RS 11–17 (n = 891) | Total (n = 1396) |
|---|---|---|---|
RS: mean, median (range) | 7, 8 (0–10) | 14, 14 (11–17) | 12, 12 (0–17) |
Age at diagnosis | |||
 Mean, median (range); years | 58, 59 (25–84) | 56, 55 (22–90) | 57, 57 (22–90) |
  < 40 years; n (%) | 21 (4.2%) | 42 (4.7%) | 63 (4.5%) |
  40–49 years; n (%) | 111 (22%) | 220 (24.7%) | 331 (23.7%) |
  ≥ 50 years; n (%) | 373 (73.9%) | 629 (70.6%) | 1002 (71.8%) |
Tumor size: mean, median (range); cm | 1.31, 1.2 (0.4–5.8) | 1.32, 1.2 (0.3–4.7) | 1.32, 1.2 (0.3–5.8) |
Multifocality; n (%) | 123 (24.4%) | 174 (19.5%) | 297 (21.3%) |
LVI; n (%) | 90 (19.8%) | 176 (17.8%) | 266 (19.1%) |
Local treatment; n (%) | |||
 BCS only | 15 (3%) | 33 (3.7%) | 48 (3.4%) |
 BCS and radiation therapy | 319 (63.2%) | 611 (68.6%) | 930 (66.6%) |
 Total mastectomy | 171 (33.9%) | 243 (27.3%) | 414 (29.7%) |
 Total mastectomy and radiation therapy | 0 | 4 (0.4%)b | 4 (0.3%)b |
Systemic therapy; n (%) | |||
 Endocrine therapy alone | 462 (91.5%) | 722 (81%) | 1184 (84.8%) |
 Endocrine therapy and chemotherapya | 22 (4.4%) | 147 (16.5%)a | 169 (12.1%)a |
 No systemic therapy | 21 (4.2%) | 22 (2.5%) | 43 (3.1%) |
Median follow-up (range); months | 52 (0.9–108.3) | 52.2 (1–93) | 52 (0.9–108.3) |
LRR; n (%) | 5 (1%) | 8 (0.9%) | 13 (0.9%) |